Since the Supreme Court opinion ruled that SIGA breached the contractual duty to negotiate in good faith, it would seem that Pharmathene won the moral battle. However, since SIGA may end up paying Pharmathene significantly less if expectation damages are not awarded, it would appear that SIGA has won the financial battle.
If SIGA won the financial battle the stock price would be significantly higher than it is right now ($3.75). Obviously, something other than PIP's moral victory is keeping SIGA down. No third party has stepped in to buy either company or both PIP and SIGA. I think its time to question both the hype tied to thes companies and the worth of the supposedly valuable drug.